{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:07:35Z","timestamp":1785377255264,"version":"3.55.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Lake Erie College of Medicine","award":["J2022.2"],"award-info":[{"award-number":["J2022.2"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Urinary tract infections (UTI) are a disease of serious impact on every country in the world. Growing resistance has decreased the efficacy of many antimicrobial options. Aminoglycosides, like gentamicin, have long been used to treat gram-negative bacteria including UTIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The goal of this study was to compare single dose gentamicin to standard oral seven-day treatment in the emergency department for uncomplicated cases of acute uncomplicated cystitis in premenopausal women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a randomized, open-label clinical trial of women at least 18\u00a0years of age, that were premenopausal, non-pregnant, with clinical signs of UTI and nitrite positive urine in the emergency department. Patients received either single-dose gentamicin or standard care for 7\u00a0days. Patients were contacted by telephone at 7 and 30\u00a0days and asked about clinical resolution of their UTI. The primary outcome of this study was symptom resolution at 7\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among those with 7-day telephonic follow-up, self-reported symptom resolution was 83.3% (25\/30) among gentamicin treated patients and 48.1% (13\/27) in the standard care group (X\n                      <jats:sup>2<\/jats:sup>\n                      = 7.917,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Single-dose gentamicin for acute uncomplicated cystitis in premenopausal, nitrite positive women was an appropriate UTI treatment and more effective than standard care for symptom resolution at 7-days in our patient population. This strategy has the potential to revolutionize treatment by offering an antibiotic with high sensitivities, high efficacy, simple administration in many different healthcare settings, 100% compliance, and increased patient satisfaction for acute cystitis treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08971900251322368","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T17:18:21Z","timestamp":1739812701000},"page":"518-524","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-Dose Gentamicin vs Standard Care for Treatment of Acute Uncomplicated Cystitis in Premenopausal Women: A Randomized Trial"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5091-292X","authenticated-orcid":false,"given":"Vincent","family":"Peyko","sequence":"first","affiliation":[{"name":"St. Elizabeth Boardman Hospital"},{"name":"St. Elizabeth Boardman Hospital, Boardman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Sieger","sequence":"additional","affiliation":[{"name":"Western Reserve Hospital Partners"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Dombroski","sequence":"additional","affiliation":[{"name":"St. Elizabeth Boardman Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.4103\/UA.UA_104_19"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25730"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02165-18"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/emp2.12694"},{"key":"e_1_3_4_7_2","first-page":"419","article-title":"Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis","volume":"7","author":"Srivastava K","year":"2013","unstructured":"Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419-434.","journal-title":"Patient Prefer Adherence"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suw048"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf046"},{"key":"e_1_3_4_10_2","first-page":"99","article-title":"Asymptomatic bacteriuria","volume":"102","author":"Colgan R","year":"2020","unstructured":"Colgan R, Jaffe G, Nicolle L. Asymptomatic bacteriuria. Am Fam Physician. 2020;102:99-104.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.14268"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.04.014"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S146397"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215588241"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02897-15"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","unstructured":"Schmiemann G Gagyor I Hummers-Pradier E Bleidorn J. Resistance profiles of urinary tract infections in general practice \u2013 an observational study. BMC Urol. 2012;33. doi:10.1186\/1471-2490-12-33","DOI":"10.1186\/1471-2490-12-33"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3627"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad287"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.09.061"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad430"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07167-y"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/665724"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu521"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.20.2207"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw396"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1104429"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-013-0020-5"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32817-4"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3941\/jrcr.v13i6.3656"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.085"},{"key":"e_1_3_4_31_2","volume-title":"Shingrex [package insert]","year":"2023","unstructured":"Shingrex [package insert]. Rixensart, Beligium: Glaxo Smith Kline; 2023."},{"key":"e_1_3_4_32_2","volume-title":"Gentamicin [package Insert]","year":"1993","unstructured":"Gentamicin [package Insert]. Auckland, New Zealand: Pfizer; 1993."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2000.01312.x"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000377"},{"key":"e_1_3_4_35_2","first-page":"1811","article-title":"Aminoglycosides: a practical review","volume":"58","author":"Gonzalez U","year":"1998","unstructured":"Gonzalez U, Spencer J. Aminoglycosides: a practical review. Am Fam Physician. 1998;58:1811-1820.","journal-title":"Am Fam Physician"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251322368","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251322368","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251322368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:48Z","timestamp":1777509228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251322368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/08971900251322368"],"URL":"https:\/\/doi.org\/10.1177\/08971900251322368","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]}}}